Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:51c9:0:b0:451:8158:aa77 with SMTP id n9csp1402931wrv; Thu, 14 May 2026 17:58:24 -0700 (PDT) X-Received: by 2002:a05:6214:4884:b0:8c6:1ee2:217e with SMTP id 6a1803df08f44-8ca0f6277e9mr37287876d6.18.1778806704535; Thu, 14 May 2026 17:58:24 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1778806704; cv=none; d=google.com; s=arc-20240605; b=fCFnvBa/5eQrxRL2CxLZ2tuWx9sSFHlK5VAC6XaxsUXnr2yYp/Vo1Tvufb5d7BAk69 S0aU6wqINQe19MiXr97DjlC+Hr+kKa78XcRYVaxNMQhaSDpF0c45as6ESFdlPoUkCUHO 7CaKL63uz3r4FLZ1kYoshb2LDdVJG7b58zsY8Q9ceHzA6LB6xIwu0aAHN/4ClY6rv4h8 +Ab0goA4k4Zx2kH02Ml8BRFY2lDforaHrOtt3HyeJVRgXXQcCaYKeW5pVyf8jZT+pcmS v5FkrRIzTPDztWPF+YSIbpCtoSK38Ok19elFpJtLCHPZQ17eY1Gc+xHw4D2fFbIYnrn2 yu5w== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=VJxGWWs2wlxSkWjdR3Clq/iVueI6Zjbc4GmSadCMi+s=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=G9etV/epxKhRlWUiYotGgfVuqdPG9EtjztyAD3gmERZrLXM5XuuTnvE9BFkewnIj06 75gyk6xyuYIiUlV+eyPTHpdIlIYI9AbBs0g2c4nTkpiweBELZsKyne8/fzxj9n7ZIQ9j sys9fvY8dllxpYi0vIFfxjaSMsiQioy/vv3iLqjx319G/TPHrMjnKcU8cn+21HjEazjS bgROw2xXgh4rXoLV08jCBCzXHV+gT2p7u935U8YcQxq/ijdI/xD0/+eEGzAp0Q/r0fDL C8mFivm3K3X1hV/BJJaAhT5aSrhgFwDjNh5B522JTJDHRneFwCyesVLt+mXDy3VChptg 1YTg==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=Wq3wIZlH; dkim=pass header.i=@mailgun.org header.s=mg header.b=WJkl7Vgb; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.36 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v536.v5375b7fa.use4.send.mailgun.net (v536.v5375b7fa.use4.send.mailgun.net. [159.112.244.36]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-8c90bb81830si53073076d6.277.2026.05.14.17.58.24 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 14 May 2026 17:58:24 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.36 as permitted sender) client-ip=159.112.244.36; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=Wq3wIZlH; dkim=pass header.i=@mailgun.org header.s=mg header.b=WJkl7Vgb; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.36 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1778806704; x=1778813904; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=VJxGWWs2wlxSkWjdR3Clq/iVueI6Zjbc4GmSadCMi+s=; b=Wq3wIZlHciCeacc6cyw+uJwvc/t5kd+GDhhGgVxt6MyotCu3GmtwxUTOouBdIL98DA84704mNHx2fYDUHZh2imT1UwTSQXZ/kZajKdtjTbU5bjduKkxKKDNOLoCBYThScUda00Q7gTsW/k6RAB+Pj0bKb1k9Uk4zIhNabGX2goo= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1778806704; x=1778813904; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=VJxGWWs2wlxSkWjdR3Clq/iVueI6Zjbc4GmSadCMi+s=; b=WJkl7VgbYrHWoToqtcjPXY7uP5rxjVIscrfIMQBLakIuSvsuzpe3xolOruS9o8aM7w6dWrIP+bDOOH0kYX6B3j2evTbIaqdv/7F2A25ywKBx3AzDmwS6qkuXjOY/dnGKMaMDxZx/LKbFNwR8MJjyxSGbHU+c1lGAmHdOvb09QZQ= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by b565a8099f58466dec611b795b5cb1f28b54af3379184bd5ea095169bf794b69 with HTTP id 6a066faf4e0c6b7819599436; Fri, 15 May 2026 00:58:23 GMT X-Mailgun-Sending-Ip: 159.112.244.36 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="4c0cb27a4ba14f62a841ab3407b2f08626a259b7adc5a5499284b67c3573" Subject: Following Up on the Bioglutide Sample Janoshik Tested From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260515005814.3.38e9ffab129aad4e@mg-d0.substack.com> Date: Fri, 15 May 2026 00:58:14 +0000 Feedback-Id: post-197785713:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1778806703827", "is_freemail": "true", "post_audience": "everyone", "post_id": "197785713", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --4c0cb27a4ba14f62a841ab3407b2f08626a259b7adc5a5499284b67c3573 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/following-u= p-on-the-bioglutide-sample One of the members of the community sent this over and I want to walk you t= hrough it, because it=E2=80=99s one of the clearest examples I=E2=80=99ve s= een of why independent identification testing matters in this space. If you caught my Janoshik podcast episode [ https://substack.com/redirect/f= a47beae-f6e1-48ed-b340-7bf60bb357a7?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfd= amY0krRXGMy3p768BWtuZifRB-Zs ], Peter told a story about a research sample = of Bioglutide that came through his lab for identification. The marketing p= ositioned it as a brand new compound. What the analysis actually returned w= as two existing GLPs blended together. Nothing novel. Just relabeled invent= ory. This story on X follows the same pattern, with even more thorough analytica= l work behind it. Let me walk you through it. The Setup A compound called Bioglutide, also known as NA-931, has been circulating in= the research market. The marketing pitch is impressive on paper. It has be= en positioned as a first-in-class oral quadruple agonist =E2=80=94 meaning = a single compound that activates four different receptors at once: GLP-1, G= IP, glucagon, and IGF-1. If real, that would be a genuinely novel molecule = worth studying. Here is the catch. For any legitimate research compound, you should be able= to find a few basic things publicly: The sequence The molecular weight The structure An independently verified reference standard that labs can compare samples = against For Bioglutide, none of that exists. No published sequence. No confirmed st= ructure. No reference standard. Just marketing. The Test Kimera Chems decided to find out what was actually in the raw material bein= g sold under that name. They acquired raws being marketed as NA-931 from a = Chinese API supplier and submitted them to NuMega Resonance Labs, an indepe= ndent analytical facility. They requested two things: Proton NMR scan =E2=80=94 essentially a structural fingerprint of the molec= ule Mass spectrometry =E2=80=94 which determines molecular weight The smart part of the request was that they specifically asked NuMega to sc= an the full range up to 2,500 m/z. Here is why that matters. A real glutide= -class peptide, like Bioglutide is claimed to be, should weigh somewhere be= tween 4,000 and 5,000 Daltons. That is a large peptide. If the sample reall= y was what the label claimed, the mass spec would show clear evidence of a = peptide in that range, including the multiply charged envelope you would ex= pect from a molecule that size. What Came Back The mass spec showed a parent mass of about 154 Daltons. Not 4,000. Not 5,000. One hundred and fifty four. That is not a peptide agonist. That is a small molecule. Roughly thirty tim= es lighter than what Bioglutide is claimed to be. The NMR backed it up. The structural fingerprint matched cyclo(Pro-Gly), al= so known as Traneurocin, also known as NA-831. Notice the names. NA-931 was what was purchased. NA-831 is what the analysi= s identified. One digit off. Completely different compound. Here is the Kicker NA-831 is a real compound. It exists. It has a known structure. It has been= investigated. But it has nothing to do with metabolic pathways, GLP-1 rece= ptor activity, or anything Bioglutide is positioned as. NA-831 is a small cyclic dipeptide tied to Biomed=E2=80=99s neurological re= search pipeline. It has been studied in connection with Alzheimer=E2=80=99s= , dementia, and cognitive decline models. Its proposed mechanism involves m= odulating BDNF in the hippocampus to support neuronal resilience. So a research subject receiving administration of material labeled NA-931 w= ith the expectation of studying a quadruple metabolic agonist would actuall= y be exposed to a neuroactive cyclic dipeptide. Completely different pharma= cology. Completely different downstream effects. Any data collected under t= hat protocol would be meaningless because the input compound was never what= the label claimed. Why This Matters This is the exact pattern Peter described on the podcast. A compound gets h= yped before anyone has independently verified what it actually is. Vendors = race to list it. Raws and finished products flood the market. Buyers acquir= e it based on marketing claims. And when somebody finally pays for proper i= dentification testing, the contents do not match the label. This is why I push so hard on COAs, independent third party testing, and ve= ndor transparency. It is also why I stay cautious about brand new compounds= that arrive with big claims and no verifiable chemistry behind them. Ident= ification testing is not optional for serious research =E2=80=94 it is the = floor. The full write-up is worth your time. It walks through the NMR data, the ma= ss spec data, and the broader mess around how Bioglutide is being marketed = and sold despite no one being able to verify what it actually is. Read the full thread on X [ https://substack.com/redirect/f274a32f-65a4-459= 6-92b3-48130bbce16f?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768= BWtuZifRB-Zs ] Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOemM0TlRjeE15d2lhV0YwSWpveE56YzRPR= EEyTnpBekxDSmxlSEFpT2pFNE1UQXpOREkzTURNc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Lm91VTJheXFoRnlwZ2xubGlSNUVzVTFsc0l= UUGNSaDZjYXVOQXhvTWFDQUkiLCJwIjoxOTc3ODU3MTMsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc4ODA2NzAzLCJleHAiOjIwOTQzODI3MDMsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.pggMsEnojaR3FGPhUofufXUi0xDS7J3kreQ-K_I= YrKQ? --4c0cb27a4ba14f62a841ab3407b2f08626a259b7adc5a5499284b67c3573 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = Following Up on the Bioglutide Sample Janoshik Tested=3D""
One of the members of the community sent this = over and I want to walk you through it, because it’s one of the clear= est examples I’ve seen of why independent identification testing matt= ers in this space.
͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­
Forwarded this email? Subscribe here for more

Following Up o= n the Bioglutide Sample Janoshik Tested

Der= ek
<= tbody>
May 15
 <= /td>
=
3D""
3D""
3D""
3D""
READ = IN APP3D""
=
 

One of the members of the community sent this over and I want to wal= k you through it, because it’s one of the clearest examples I’v= e seen of why independent identification testing matters in this space.

=

If you caught my Janoshik podcast episode, Peter told a story about a= research sample of Bioglutide that came through his lab for identification= =2E The marketing positioned it as a br= and new compound. What the analysis ac= tually returned was two existing GLPs blended together. Nothing novel. Just= relabeled inventory.

<= /div>

This story on X follows the same pattern, with even more = thorough analytical work behind it. Let me walk you through it.

The Setup

A compound called = Bioglutide, also known as NA-931, has been circulating in the research market. The marketing pitc= h is impressive on paper. It has been positioned as a first-in-class oral <= /span>quadruple agonist — meaning a single com= pound that activates four different receptors at once: GLP-1, GIP, glucagon= , and IGF-1. If real, that would be a genuinely novel molecule worth studyi= ng.

Here is the catch. For any legitimate research c= ompound, you should be able to find a few basic things publicly:

  • The sequence

  • The molecular weight

  • The structure

  • An independently verified reference standard that labs can compare sam= ples against

For Bioglutide, none of that exists.= No published sequence. No confirmed structure. No reference standard. Just= marketing.

The Test

Kim= era Chems decided to find out what was actually in the raw material being s= old under that name. They acquired raws being marketed as NA-931 from a Chi= nese API supplier and submitted them to NuMega Resonance Lab= s, an independent analytical facility.

Proton NMR scan — essentia= lly a structural fingerprint of the molecule

  • Mass spectrometry — which determines m= olecular weight

    • The smart part of th= e request was that they specifically asked NuMega to scan the full range up= to 2,500 m/z. Here is why that matters. A real glutide-class peptide, like= Bioglutide is claimed to be, should weigh somewhere between 4,000 and 5,000 Daltons. That is a large peptide. If the sa= mple really was what the label claimed, the mass spec would show clear evid= ence of a peptide in that range, including the multiply charged envelope yo= u would expect from a molecule that size.

    The mass spec showed a parent mass = of about 154 Daltons.

    = Not 4,000. Not 5,000. One hundred and fifty four.

    That is not a peptide agonist. That is a small molecule. Roug= hly thirty times lighter than what Bioglutide is claimed to be.

    =
    = 3D"image.png"

    The NMR backed it up= =2E The structural fingerprint matched=20= cyclo(Pro-Gly)= , also known as Traneurocin, also known= as NA-831.

    Noti= ce the names. NA-931 was what was purchased. = NA-831 is what the analysis identified. One d= igit off. Completely different compound.

    Here is the Kicker

    NA-831 is a real compound. It exists. = It has a known structure. It has been investigated. But it has nothing to d= o with metabolic pathways, GLP-1 receptor activity, or anything Bioglutide = is positioned as.

    NA-831 is a small cyclic dipeptide tied t= o Biomed’s neurological research pipeline. It has been studied in con= nection with Alzheimer’s, dementia, and cognitive decline models. Its= proposed mechanism involves modulating BDNF in the hippocampus to support = neuronal resilience.

    So a research subject receiving admini= stration of material labeled NA-931 with the expectation of studying a quad= ruple metabolic agonist would actually be exposed to a neuroactive cyclic d= ipeptide. Completely different pharmacology. Completely different downstrea= m effects. Any data collected under that protocol would be meaningless beca= use the input compound was never what the label claimed.

    Why This Matters

    This is the exact pattern Peter= described on the podcast. A compound gets hyped before anyone has independ= ently verified what it actually is. Vendors race to list it. Raws and finis= hed products flood the market. Buyers acquire it based on marketing claims.= And when somebody finally pays for proper identification testing, the cont= ents do not match the label.

    This is why I push so ha= rd on COAs, independent third party testing, and vendor transparency. It is= also why I stay cautious about brand new compounds that arrive with big cl= aims and no verifiable chemistry behind them. Identification= testing is not optional for serious research — it is the floor.

    The full write-up is worth your time. It walks through= the NMR data, the mass spec data, and the broader mess around how Biogluti= de is being marketed and sold despite no one being able to verify what it a= ctually is.

    Re= ad the full thread on X

    Upgrade to p= aid

    You're currently a free subscriber to Research Radar. For the full experie= nce, upgrade your subscription.

    Upgrade to paid

    =
     
    3D""Share
     
     
    =
    3D""Like
    3D""Comment
    =
    3D""Restack
    =  

    © 2026 Derek Pruski548 Market Street PMB 72296, San Francisco, CA 94104
    Unsubscribe

    3D"Start

    <= /td>
    3D""=3D"" --4c0cb27a4ba14f62a841ab3407b2f08626a259b7adc5a5499284b67c3573--